Close Menu

NEW YORK (GenomeWeb) – Quadrant Biosciences said today that it has entered three new licensing agreements with SUNY Upstate Medical University and Penn State University for the global commercialization of epigenetic biomarkers for autism spectrum disorder, Parkinson's disease, and concussion.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.